Introduction
============

In 2012, 1.7 million women worldwide were diagnosed with breast cancer (BC), and 521,900 women died from it.[@b1-bctt-8-093] These statistics include all subtypes of BC, but it is well known that BC is not a homogeneous disease. Four major intrinsic subtypes have been identified by genomic studies: the luminal subtypes A and B, which express hormone receptor-related genes, basal-like (BL) BC, and HER2-positive BC.[@b2-bctt-8-093],[@b3-bctt-8-093]

Triple-negative BC (TNBC) is a heterogeneous group characterized by the lack of expression of hormonal receptors and the absence of HER2 overexpression. The definition of negative estrogen receptor (ER) status by immunohistochemistry (IHC) is not concordant in the literature, with some definitions considering ER expression to be significant only if at least 10% of tumor cells express the receptors. However, the St Gallen guidelines,[@b4-bctt-8-093] the American Society of Clinical Oncology,[@b5-bctt-8-093] and the American College of Pathology[@b5-bctt-8-093] have defined TNBC as BC with less than 1% of tumor cells expressing the ER and progesterone receptors via IHC.

TNBC represents approximately 15% of all BCs and is characterized by shorter overall survival and an early peak of distant recurrences at 3 years after diagnosis. The majority of deaths occur in the first 5 years following initial diagnosis. Late tumor recurrences are unusual with this BC subtype and recurrences generally are not observed after 8 years.[@b6-bctt-8-093] TNBC has an aggressive clinical behavior, with a higher risk of both local and distant relapses that frequently present as visceral and/or brain metastases.[@b7-bctt-8-093],[@b8-bctt-8-093] TNBCs are frequently assimilated into the intrinsic subgroup of BCs that have been described in microarray-based expression profiling research as the BL molecular phenotype.[@b2-bctt-8-093] However, not all TNBCs display a BL molecular phenotype on gene expression arrays. Indeed, 75% to 80% of TNBCs are actually BL cancers. Some markers that have been identified by IHC in tumor cells are also found in normal basal/myoepithelial cells of the breast, including high-molecular-weight basal cytokeratin 5/6 (CK5/6), CK14, B crystallin, CK17, epidermal growth factor receptor (EGFR) HER1, caveolin 1/2 (CAV1/2), vimentin, fascin, c-Kit, and P-cadherin. TNBC is less likely to express epithelial markers such as E-cadherin.[@b9-bctt-8-093]--[@b11-bctt-8-093] Similarly, not all BL BCs are TNBC: up to 54% of cancers in the BL subgroup do not have a TN phenotype on IHC.[@b11-bctt-8-093],[@b12-bctt-8-093] Indeed, some BL cancers express ER or overexpress HER2. Currently, there is no international definition of TNBC/BL cancer, but the most appropriate approach to use in the absence of access to molecular profiling is a panel of four antibodies (ER, HER2, CK5/6, and EGFR HER1), which can best characterize BL tumors based on IHC criteria.[@b9-bctt-8-093]

In a large population-based study from the California Cancer Registry, TNBCs were significantly more frequent in women under the age of 40 years.[@b13-bctt-8-093] TNBCs are also more frequent in women who are germ-line *BRCA1*/*2* mutation carriers and in women of black race or Hispanic ethnicity.[@b14-bctt-8-093] Up to 19.5% of patients suffering from TNBC present *BRCA1*/*2* mutations.[@b15-bctt-8-093],[@b16-bctt-8-093] For this reason, it is recommended to test all women under the age of 60 years suffering from TNBC for *BRCA1*/*2* mutations (National Comprehensive Cancer Network guidelines).[@b17-bctt-8-093]

Currently, only chemotherapy (CT) is routinely used as systemic treatment in patients with TNBC, although in some countries bevacizumab is still added to CT in advanced BC (ABC), even in the absence of any demonstrated overall survival benefit. However, intense research is ongoing to identify actionable targets. A large number of clinical trials are ongoing that aim to improve current treatment outcomes. Better knowledge of the biology of this BC subgroup will allow us to evaluate new specific treatment approaches dedicated to this hard-to-treat disease.

We first review the available data on molecular heterogeneity and *BRCA1*-associated TNBC/BL BC. Thereafter, we discuss the current treatment options and some promising new treatment approaches that include targeted treatments.

Understanding TNBC heterogeneity
================================

Before molecular profiling confirmed the important heterogeneity in the biology of TNBC, clinical data had already indicated the existence of heterogeneous treatment responses and long-term outcomes. Some patients respond very well to neoadjuvant CT and present a pathologic complete response (pCR) at the time of surgery. Other patients present no response to neoadjuvant CT and suffer from early relapse after surgery.[@b6-bctt-8-093],[@b18-bctt-8-093],[@b19-bctt-8-093] Unfortunately, predictive factors that allow the identification of patients who will present a pCR and those who will not benefit from CT at the time of diagnosis do not exist.

The vast majority of TNBCs are high-grade invasive ductal carcinomas, but some rare cases are histologically different, such as adenoid cystic carcinoma, secretory carcinoma, medullary carcinoma, and metaplastic carcinoma. The prognosis depends on the TNBC pathological subtype.[@b20-bctt-8-093]--[@b22-bctt-8-093]

The Cancer Genome Atlas Research Network used six methods to analyze primary BCs: genomic DNA copy-number arrays, DNA methylation, exome sequencing, messenger-RNA arrays, microRNA sequencing, and reverse-phase protein arrays.[@b23-bctt-8-093] Only in three genes did somatic mutations occur at a frequency higher than 10% across all BCs: *TP53*, *PIK3CA*, and *GATA3*. Specific mutations are more frequent in some BC subtypes. In TNBC/BL cancers, the most frequent findings were the loss of *TP53*, *RB1*, *BRCA1*, and *PIK3CA*.[@b23-bctt-8-093] Known drivers, such as *P53*, *PIK3CA*, and *PTEN*, have the highest clonal frequencies, but at the time of diagnosis, some patients present low clonality, while others have a more extensive clonal evolution, illustrating further important heterogeneity in TNBC.[@b24-bctt-8-093]

Subtyping TNBC: clinical implications
=====================================

More recently, gene expression profiling of 587 TNBCs identified six different subtypes: BL1 and BL2, an immunomodulatory (IM) subtype, a mesenchymal subtype, a mesenchymal stem like (MSL) subtype, and a luminal androgen receptor (LAR) subtype.[@b25-bctt-8-093] The strengths of this study were to identify further the molecular drivers in corresponding cell-line models to provide preclinical platforms for the development of effective therapies ([Table 1](#t1-bctt-8-093){ref-type="table"}). For example, the authors showed that BL1 lines were the most sensitive to cisplatin and that the mesenchymal and MSL lines were most sensitive to the Abl/Src inhibitor dasatinib.[@b20-bctt-8-093]

The same group used the intrinsic subtype tool to examine the composition of each TNBC subtype. The authors showed that all TNBC subtypes except MSL and LAR were composed primarily of the BL intrinsic subtype (BL1 \[99%\], BL2 \[95%\], IM \[84%\] and mesenchymal \[97%\]). The LAR subtype is classified as HER2 (74%) and luminal B (14%), and the MSL subtype includes BL (50%), normal-like (28%), and luminal B (14%).[@b20-bctt-8-093]

Other gene expression analyses have also defined a claudin-low tumor subtype.[@b26-bctt-8-093] Molecular characterization showed that these tumors are enriched in epithelial-to-mesenchymal transition, immune system response, and stem-like features, but show low expression of luminal and proliferation-associated genes.[@b27-bctt-8-093]

Another group used genomic profiling of 198 TNBCs to identify four TNBC subtypes: LAR, mesenchymal, BL immunosuppressed, and BL immunoactivated.[@b28-bctt-8-093] If compared with the results reported by Lehmann et al,[@b25-bctt-8-093] LAR and mesenchymal tumors fall into the LAR and MSL subtypes.

The comprehensive analysis of TNBC can lead to the improved selection of study populations that have the highest probability of responding to specific treatments. For example, TNBC molecular subtypes may respond differently to CT. The clinical validity of the genomic classification was indeed confirmed by a retrospective analysis of the response to neoadjuvant CT. The overall pCR in this study was 28%. In the BL1 subtype, the pCR was the highest (51%),[@b29-bctt-8-093] in comparison to 0 in the BL2 subtype and 10% in the LAR subtype, clearly showing the need to develop alternative treatments for some subgroups.

In the future, the evaluation of heterogeneity in TNBC and subtyping may lead to different therapeutic strategies. Potential targets and approaches include DNA damage and repair, immunomodulation, hormone receptor modulation, and signaling pathway inhibition.

Prospective trials will help us better understand the role of subtyping in the prediction of not only pCR but also long-term patient outcomes. New therapeutic strategies are needed for subgroups with the poorest therapeutic responses to standard CT.

DNA-damaging chemotherapy and DNA repair targets
================================================

*BRCA1* mutation and "BRCAness"
-------------------------------

Many external or internal agents, such as ultraviolet light, ionizing radiation, CT, and chemical substances or products of normal cellular metabolism, including oxidation and hydrolysis, affect double-stranded DNA. DNA repair mechanisms are important for maintaining the stability and integrity of the genome, and include nucleotide- and base-excision repair, homologous recombination, end joining, mismatch repair, and telomere metabolism.[@b30-bctt-8-093],[@b31-bctt-8-093] Inherited defects in one of these important genes can lead to cancer, as observed in the *BRCA1*/*2* syndrome. DNA repair mechanisms are classified as the repair of single- or double-stranded damage. *BRCA1* and *BRCA2* are important proteins in the homologous recombination process when damage leads to breaks in both DNA strands. The proteins have also been implicated in other fundamental cellular processes, such as cell cycle control and transcription.[@b32-bctt-8-093]

BC in *BRCA1* germ-line mutation carriers most often displays a TN phenotype, as indicated by IHC and genomic studies.[@b33-bctt-8-093] Due to the similarity between sporadic TNBC and familial *BRCA1* cancers, the concept of BRCAness has been developed.[@b34-bctt-8-093]--[@b36-bctt-8-093] In sporadic cancers, *BRCA1* is inactivated by an epigenetic mechanism: the aberrant methylation of cytosine residues in CpG dinucleotides.[@b37-bctt-8-093] Aberrant methylation of the *BRCA1* promoter is found in 11%--14% of sporadic BCs.[@b35-bctt-8-093],[@b38-bctt-8-093] In contrast, *BRCA2* tumors lack a clear pathological phenotype.

Knowledge of DNA repair mechanism defects leads to some specific treatment approaches in TNBC. These tumors present potentially higher sensitivity to DNA-damaging agents, such as platinum salts. The concept of "synthetic lethality" is also tested in the clinic, with the development of drugs (poly ADP-ribose polymerase \[PARP\] inhibitors) that target single-stranded DNA repair when homologous recombination is defective in *BRCA*-mutant tumors or in BRCAness tumors.[@b39-bctt-8-093] Several studies have attempted to find a biomarker of homologous recombination deficiency (HRD) with the aim of better predicting responders to PARP inhibitors and DNA-damaging chemotherapies.[@b40-bctt-8-093]--[@b42-bctt-8-093]

Platinum-based chemotherapy
===========================

Metastatic TNBC
---------------

The use of platinum compounds in metastatic BC was evaluated many years ago. Objective responses have been reported in ABC.[@b43-bctt-8-093] Some retrospective analyses have also suggested the occurrence of increased survival with platinum-based CT in patients with advanced TNBC.[@b44-bctt-8-093],[@b45-bctt-8-093]

A prospective Phase II study showed activity of platinum agents, including cisplatin (75 mg/m^2^/3 weeks) and carboplatin (area under the curve 6/3 weeks), in patients with metastatic TNBC, especially in patients with germ-line *BRCA1*/*2* (gBRCA1/2) mutations.[@b46-bctt-8-093] A total of 86 patients were enrolled. The overall response rate was 25.6%, but in patients with germ-line *BRCA1*/*2* mutations, the response rate increased to 54.5%. Interestingly, using a measure of DNA repair function, those authors also identified patients without mutations who had the potential to benefit from platinum therapy. They used two HRD assays to characterize *BRCA*-like genomic instability: the HRD large-scale state transition assay and the HRD loss of heterozygosity assay. They observed that patients who presented higher values in these assays also responded better to platinum-based treatments, even in the absence of germ-line mutations.[@b46-bctt-8-093]

A prospective randomized trial comparing docetaxel with carboplatin in patients suffering from TNBC was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS).[@b47-bctt-8-093] Those authors observed similar results for unselected TNBC, but patients with *BRCA1*/*2* mutations experienced a significantly higher response rate and improved progression-free survival (PFS) when receiving carboplatin in comparison to docetaxel.

Early TNBC
----------

The rate of pCR after anthracycline- and taxane-based neoadjuvant CT is higher in TNBC (±30%) than in luminal BC. In addition, patients presenting pCR after neoadjuvant CT generally have a better prognosis compared to patients who do not present pCR at the time of surgery.[@b48-bctt-8-093],[@b49-bctt-8-093] Unfortunately, patients suffering from TNBC who present residual disease after neoadjuvant CT have very poor outcomes. New therapies should be evaluated in patients who present residual disease after neoadjuvant CT. Retrospective research has suggested improved outcomes in terms of pCR when cisplatin is added to the neoadjuvant treatment. Byrski et al[@b50-bctt-8-093] published a retro spective analysis of 6,903 patients, including 102 patients with the germ-line *BRCA1* mutation. The highest pCR rate was reported in germ-line *BRCA1*-mutation carriers who received neoadjuvant cisplatin therapy: 24% of the *BRCA1*-mutation carriers had pCR, but in the subgroup that received cisplatin, a much higher rate of 83% pCR rate was observed.[@b50-bctt-8-093]

Five randomized studies evaluated the addition of carboplatin to standard neoadjuvant therapy[@b51-bctt-8-093]--[@b55-bctt-8-093] ([Table 2](#t2-bctt-8-093){ref-type="table"}). Experimental arm 1 from the I-SPY 2 trial showed an increased rate of pCR in patients with TNBC if standard CT (paclitaxel/anthracycline--cyclophosphamide) was combined with carboplatin and the PARP inhibitor veliparib. A confirmatory Phase III trial is underway.[@b55-bctt-8-093] The GeparSixto[@b52-bctt-8-093] and CALGB 40603[@b53-bctt-8-093] trials showed increased rates of pCR with carboplatin, but toxicities were also more frequent and more significant if carboplatin was added. More dose reductions and early study discontinuations occurred due to these toxicities. The incidence of grade 3--4 hematological toxicities almost doubled. Data on late toxicities are missing, because the median follow-up period was only 3 years. Recently, at the 2015 SABCS, improved overall survival for patients receiving carboplatin was reported in the GeparSixto trial.[@b56-bctt-8-093] A subsequent Phase III trial evaluating two dose-dense regimens is recruiting participants (GeparOcto, NCT02125344).[@b57-bctt-8-093] In contrast, in the CALGB 40603 trial, despite significantly higher pCR rates, neither carboplatin nor bevacizumab showed improved event-free or overall survival. In addition, not all Phase II trials evaluating the use of carboplatin have shown improvements in pCR.[@b54-bctt-8-093]

Currently, platinum compounds are not included in the guidelines for the treatment of early TNBC, but their role should be discussed in some specific cases, such as patients with a higher risk of relapse or requiring rapid disease control. Some recommend the use of carboplatin only for patients with known *BRCA* mutations,[@b58-bctt-8-093] but the available data are conflicting, as illustrated by the GeparSixto trial, which showed better outcomes when using carboplatin in patients with TNBC, independently of germ-line *BRCA* status. Interestingly, the GeparQuinto trial showed a statistically higher pCR rate with a classical sequential anthracycline--taxane regimen and a trend for better disease-free survival (hazard ratio 0.64, *P*=0.06) in the subgroup of patients with *BRCA* mutations (82 of 471 patients).[@b59-bctt-8-093] These results suggest higher chemosensitivity and better prognosis in patients with germ-line *BRCA* mutations, even without platinum compounds. Participation in clinical trials is recommended in the neoadjuvant and postneoadjuvant setting in the absence of pCR to better define the optimal standard systemic therapy for TNBC ([Table 3](#t3-bctt-8-093){ref-type="table"}).

The potential role of PARP inhibitors in TNBC
=============================================

Based on the synthetic lethality concept, PARP inhibitors were developed for the treatment of cancers with specific DNA-repair deficits, such as TNBC with *BRCA1*/*2* mutations and BRCAness TNBC.[@b35-bctt-8-093] The first drug of this class, olaparib, was approved by the US Food and Drug Administration in December 2014 as a single-agent treatment for patients with deleterious or suspected deleterious germ-line *BRCA*-mutated advanced ovarian cancer who were treated with three or more prior lines of CT. In BC, several Phase I and II trials have shown antitumor activity in *BRCA*-mutated patients ([Table 4](#t4-bctt-8-093){ref-type="table"}).[@b60-bctt-8-093]--[@b63-bctt-8-093] In the proof-of-concept Phase II trial,[@b61-bctt-8-093] Tutt et al[@b61-bctt-8-093] reported on two cohorts of patients with *BRCA1*/*2*-mutated ABC. In the first cohort (27 patients), which was assigned 400 mg twice daily, the objective response rate was 41% compared to 22% in the cohort (27 patients) treated with a lower dose (100 mg twice daily). Toxicities were mild, and included nausea and fatigue. Clinical trials are ongoing in patients with high-risk *BRCA*-mutated primary BC in the neoadjuvant and adjuvant settings.[@b64-bctt-8-093]

Androgen receptor and TNBC
==========================

The LAR subtype is characterized by luminal gene expression and is driven by the AR.[@b25-bctt-8-093] The AR is expressed in normal and malignant breast tissue, and its prevalence is variable according to the subtype of BC. Approximately 10%--15% of TNBCs express the AR.[@b65-bctt-8-093],[@b66-bctt-8-093] The LAR subtype demonstrates some similarities with the apocrine subtype. Indeed, in this histologic subtype, the gene expression profile is highly correlated with the LAR subtype. These findings indicate that the LAR subtype includes BCs with apocrine histology.[@b67-bctt-8-093],[@b68-bctt-8-093] The function of the AR is less well understood in BC than in prostate cancer. In a paper by Doane et al,[@b69-bctt-8-093] a cell line that recapitulated the molecular profile of the LAR subtype was identified. This cell line was used in preclinical models, and androgen-dependent growth was demonstrated in an estrogen-independent manner. This growth was inhibited by an AR antagonist (flutamide). This study was the first proof of concept for androgen blockade in the LAR subtype.[@b67-bctt-8-093],[@b69-bctt-8-093]

At present, results from two Phase II studies have been presented and showed a benefit for androgen blockade in this LAR subtype. The first study was conducted by Gucalp et al.[@b70-bctt-8-093] That was a multicenter Phase II study that investigated the use of bicalutamide at a dose of 150 mg daily in AR-positive, ER- and PgR-negative metastatic BC (26 patients). The majority of patients were HER2-negative. The AR was expressed in 12% of patients with ER/PgR-negative BC. This study showed a clinical benefit rate (CBR; = CR + partial response \[PR\] + stable disease \>6 months) of 19% for bicalutamide. The median PFS was 12 weeks (comparable to single-agent or combination CT in TNBC). The treatment was well tolerated, with the most common side effects including fatigue, hot flashes, limb edema, and transaminase elevations.[@b70-bctt-8-093]

The second study evaluated the activity of the next-generation antiandrogen enzalutamide in advanced AR-positive TNBC. That study was a multicenter Phase II trial conducted in two stages. In stage 1, 26 patients were evaluated for the primary end point of the CBR at 16 weeks (CBR~16~; = CR + PR + stable disease at 16 weeks). These patients received enzalutamide at a dose of 160 mg orally daily. The stage 1 result was a CBR~16~ of 42% (95% confidence interval 24%--62%), including one CR and one PR.[@b71-bctt-8-093] For the stage 2 study, 165 patients were screened, and 75 patients had AR IHC ≥10% and more than one postbaseline evaluation. Patients with TNBC had a median of one line of prior therapy. The data were presented at the American Society of Clinical Oncology's 2015 meeting and showed a CBR~16~ of 35% and a median PFS of 14.7 weeks.[@b72-bctt-8-093] Because of these results, interest in androgen blockade therapy in the LAR subtype is growing. A number of different trials are in the recruitment stage or are waiting for results ([Table 5](#t5-bctt-8-093){ref-type="table"}).

Blocking the AR pathway is a promising approach in the treatment of metastatic patients with the LAR subtype of TNBC. As an example, we would like to mention an isolated clinical case in which a heavily pretreated woman with metastatic TNBC and AR expression achieved a complete clinical response after 4 months of treatment with the AR antagonist bicalutamide.[@b73-bctt-8-093] Although this new targeted therapy is promis ing, more data are needed before it can be considered as a new validated treatment option. Future challenges related to the LAR subtype include understanding the role of the AR in tumorigenesis, understanding the escape mechanisms in AR-directed therapy, and discovering predictive biomarkers.[@b74-bctt-8-093]

Immune subtype and role of immunotherapy
========================================

BC was not previously considered to be an "immunogenic" malignancy. Nevertheless, accumulating evidence indicates the prognostic and predictive values of tumor-infiltrating lymphocytes (TILs) in BC.[@b75-bctt-8-093],[@b76-bctt-8-093] The degree of immune infiltration differs among BC subtypes. TIL levels are significantly higher in TNBC and HER2-positive BC.[@b77-bctt-8-093]--[@b79-bctt-8-093] Hormone receptor-positive disease is the subtype associated with the least robust number of TILs. Recently, several studies confirmed the prognostic value of TILs in TNBC. The lymphocyte-predominant BC subtype, which contains high levels of TILs (\>50%), is associated with improved disease-free and overall survival and pCR in the neoadjuvant setting.[@b80-bctt-8-093]--[@b82-bctt-8-093]

These findings suggest that immunomodulation could represent a new approach in the treatment of these aggressive BC subtypes.[@b79-bctt-8-093] Our current understanding suggests that the immunogenic potential of TNBC is derived at least in part from its genetic instability and high mutation rate. Tumors from patients with TNBC are more likely than tumors from patients with other subtypes to exhibit chromosomal instability and potential mutations.[@b83-bctt-8-093]

TNBC is the subtype that is most frequently associated with TILs, but only a minority of TNBCs demonstrate a high number of TILs, suggesting that IM therapy could be necessary to promote immunorecognition and increase the adaptive immune infiltrate to levels adequate for a survival benefit in the majority of patients with this BC subtype. Patients with high levels of TILs at the time of diagnosis might benefit from the use of drugs that can enhance antitumoral immune responses.

Monoclonal antibodies have been developed to block specific immune-checkpoint proteins. Some of these antibodies have already been approved by the Food and Drug Administration for the treatment of metastatic melanoma. Three categories of these antibodies exist: antibodies that block CTLA4, PD1, or PDL1.

CTLA4 was the first immune checkpoint receptor to be targeted clinically. Two antibodies are known: ipilimumab and tremelimumab. Normally, after T-cell activation, CTLA4 is upregulated on the plasma membrane, where its function is to downregulate T-cell function through a variety of mechanisms, including preventing costimulation via CD28 and its ligand -- B7. CTLA4 plays an essential role in maintaining normal immunologic homeostasis. Ipilimumab blocks CTLA4, and does not allow the T cell to interact with the receptor via CD28 on its cell surface.[@b84-bctt-8-093]

PD1 is also a negative regulator of T-cell activity that limits the activity of T cells at a variety of stages of the immune response when it interacts with its two ligands: PDL1 and PDL2. Unlike CTLA4, which is primarily believed to regulate immune responses early in T-cell activation, PD1 is primarily believed to inhibit effector T-cell activity in the effector phase within tissues and tumors.

Targeting PDL1 is a similarly promising approach to targeting PD1. However, targeting PDL1 may result in different biologic effects than targeting PD1. In addition to binding PD1, PDL1 is also believed to exert negative signals on T cells by interacting with B7. PDL1-blocking antibodies prevent this interaction, but PD1-blocking antibodies do not. Another slight difference is that PDL1 antibodies do not prevent PD1 from interacting with PDL2, although the effect of this interaction remains unknown. Nivolumab and pembrolizumab are antibodies that block PD1 on the surface of T cells and prevent those T cells from interacting with PDL1. Monoclonal antibodies that block PDL1 are being evaluated in clinical trials.[@b84-bctt-8-093],[@b85-bctt-8-093]

Investigations evaluating the presence of PD1 on TILs and PDL1 on tumor cells in BC found that immune checkpoint proteins are upregulated in many BCs, particularly the TN subtype. The reported incidence of expression is highly variable. TILs expressing PD1 appear to be found more frequently in the TN subtype than in the other subtypes. In addition, the same pattern appears to occur for PDL1. These data support the study of immune checkpoint inhibitors in TNBC.[@b86-bctt-8-093],[@b87-bctt-8-093]

Clinical trials of immunotherapy in TNBC
========================================

One of the first completed clinical trials of a PD1 monoclonal antibody (pembrolizumab) in TNBC was reported at the 2014 SABCS by Nanda et al.[@b88-bctt-8-093] That was a Phase IB study that enrolled 32 patients with TNBC who had recurrent or metastatic disease (47% of whom had had more than three lines of previous CT). The participants were all PDL1-positive. Pembrolizumab was administered intravenously at a dose of 10 mg/kg every 2 weeks, and treatment could continue indefinitely as long as the patients were stable and their disease was not clearly progressing, as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 every 8 weeks. Treatment with PD1 blockade was tolerable, with 56% of patients reporting an adverse event, but only 16% reporting grade 3--5 toxicity. Toxicity was essentially low-grade joint and muscle pain, fatigue, and nausea. One treatment-related death was caused by disseminated intravascular coagulation. Overall, 18.5% of 27 evaluable patients responded to pembrolizumab, with one (4%) CR, four (15%) PRs, and seven patients (26%) with stable disease. The median time to response was 18 weeks. The median PFS was just under 2 months. Three patients remained on pembrolizumab for at least 11 months.[@b88-bctt-8-093]

At the same meeting, initial data from a Phase I study of an anti-PDL1 monoclonal antibody (MPDL3280A, atezolizumab) in metastatic TNBC were also reported. Emens et al[@b89-bctt-8-093] showed results from 12 patients with PDL1-positive disease. Grade 3--4 toxicities occurred in 8% of patients. Although immune-related adverse events have been reported with the use of immune checkpoint inhibitor agents, only one patient in this study demonstrated grade 2 pyrexia that was potentially attributable to immune activation. In general, immune-related adverse events occurred in a minority of patients. There were no toxicity-related deaths. Although over 90% of patients had been previously treated with more than two prior regimens and one-third of those enrolled had visceral metastases, the overall response rate was 33% in the nine patients who were evaluable for efficacy (one CR and two PRs). All responses were seen within the first 6 weeks of treatment.[@b89-bctt-8-093]

Recently, data presented at SABCS 2015 encouraged the evaluation of another anti-PDL1 agent (avelumab). The trial showed promising results in a subgroup of TNBC. For those patients with TNBC and PDL1 expression on immune cells, the clinical response with avelumab was 44.4% versus 2.6% in the absence of expression.[@b90-bctt-8-093]

All of these preliminary results are promising for the use of immuno-oncology agents in TNBC. The future challenge will be the identification of tumoral immune microenvironments that improve prognosis in BC. In this way, we hope to promote efficacious antitumoral immunity for all BCs. For example, in TNBC, controlling tumor growth with conventional chemotherapies in combination with immune checkpoint inhibitors could increase response rates.[@b82-bctt-8-093],[@b91-bctt-8-093] For patients with limited T-cell infiltration, vaccine priming before or concurrent with immune checkpoint inhibitors may also result in additional clinical benefits. Many studies of further immunotherapy in BC are ongoing or planned. We hope that the best is still to come with respect to this therapy in the field of TNBC ([Table 6](#t6-bctt-8-093){ref-type="table"}).[@b92-bctt-8-093]

Growth factor overexpression in TNBC
====================================

Different growth factors are overexpressed in TNBC, such as vascular endothelial growth factor (VEGF) and EGFR. Targeting these pathways showed only limited activity in unselected TNBC. For the VEGF pathway, different trials in patients with ABC and in the adjuvant setting did not show any benefit in overall survival, even in trials dedicated to TNBC, such as the BEATRICE trial.[@b93-bctt-8-093] Similarly, for the EGFR pathway, the results have been disappointing. EGFR is overexpressed in more than 50% of TNBCs, but the rate of mutation is low (10%) and is found only in Asian populations.[@b94-bctt-8-093] Trials with anti-EGFR therapies have suggested that EGFR overexpression is not correlated with the activity of anti-EGFR agents in TNBC.[@b95-bctt-8-093],[@b96-bctt-8-093] FGFRs may be a better target. FGFRs are expressed on many different cells, and regulate cell growth, survival, migration, and differentiation. In many cancer types, FGF signaling is implicated in oncogenic behavior. Targeting this pathway is a current area of drug development, not only primarily with tyrosine-kinase inhibitors but also with monoclonal antibodies that target FGFs/FGFRs and the FGF-ligand trap.[@b97-bctt-8-093],[@b98-bctt-8-093] In BC, only 9% of tumors have FGFR1 amplification and 4% have FGFR2 amplification.[@b23-bctt-8-093],[@b99-bctt-8-093] These tumors represent a very small population, but FGFRs could be an interesting target. Participation in clinical trials is crucial for improved evaluation of the potential of this new treatment strategy according to specific FGFR alterations.[@b100-bctt-8-093]

Conclusion and perspectives
===========================

Progress in the treatment of TNBC remains an important challenge. In clinical practice, we still use standard CT (anthracyclines and taxanes). Some data in favor of the use of platinum-based CT in TNBC are now available, particularly in *BRCA*-mutation carriers. Clinical research is focused on two main axes in the neoadjuvant setting: how to increase pCR and how to improve outcomes in patients with residual disease. New targeted treatments and immunotherapeutic drugs are under development. The challenge is to drive studies on more selected patient populations due to the importance of heterogeneity in TNBC. The most promising new approaches include immunotherapy with checkpoint inhibitors, PARP inhibitors, and AR inhibitors. Furthermore, active research to discover additional specific targets in TNBC is ongoing.[@b101-bctt-8-093]
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###### 

Genomic TNBC subtypes and potential therapeutic targets

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Subtypes                    Genetic abnormalities                                                                 Potential therapeutic target
  --------------------------- ------------------------------------------------------------------------------------- --------------------------------
  BL1                         Cell cycle gene expression\                                                           PARP inhibitors\
                              DNA repair gene (ATR--BRCA pathway)\                                                  Genotoxic agents
                              Proliferation genes                                                                   

  BL2                         Growth factor signaling pathways (EGFR, MET, NGF, Wnt/β-catenin, IGF-1R)\             mTOR inhibitors\
                              Glycolysis, gluconeogenesis\                                                          Growth-factor inhibitors
                              Expression of myoepithelial markers                                                   

  Immunomodulatory            Immune cell processes (CTLA4, IL12, IL7 pathways, antigen processing/presentation)\   PD1/PDL1 inhibitors
                              Gene signature for medullary BC (rare TNBC with a favorable prognosis)                

  Mesenchymal-like            Cell motility\                                                                        mTOR inhibitors\
                              Cell differentiation\                                                                 EMT-and CSC-targeted treatment
                              Growth factor signaling\                                                              
                              EMT                                                                                   

  Mesenchymal stem-like       Similar to M^+^\                                                                      PI3K inhibitors\
                              Low proliferation\                                                                    Antiangiogenic therapy\
                              Angiogenesis genes                                                                    Src antagonist

  Luminal androgen receptor   Androgen receptor gene\                                                               Antiandrogen therapy
                              Luminal gene expression pattern\                                                      
                              Molecular apocrine subtype                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Data from Lehmann et al.[@b25-bctt-8-093]

**Abbreviations:** BC, breast cancer; BL, basal-like; CSC, cancer stem cells; DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal-transition; IGF-1R, insulin-like growth factor I receptor; IL, interleukin; IM, immunomodulatory; LAR, luminal androgen receptor; M, mesenchymal-like; MET, hepatocyte growth factor; mTOR, mammalian target of rapamycin; MSL, mesenchymal stem-like; NGF, nerve growth factor; PARP, poly ADP ribose polymerase; PD1, programmed cell death 1; PDL1, programmed death-ligand 1; PI3K, phosphatidylinositol 3-kinase; TNBC, triple negative breast cancer.

###### 

Carboplatin-based chemotherapy in neoadjuvant treatment: randomized Phase II results

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Phase II trials                                                                                                                         n     Standard chemotherapy    Standard chemotherapy + carboplatin   Toxicity
  --------------------------------------------------------------------------------------------------------------------------------------- ----- ------------------------ ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  **GeparSixto[@b52-bctt-8-093] TNBC subgroup**\                                                                                          315   pCR: 36.9% (ypT0N0)\     pCR: 53.2% (ypT0N0)\                  Increased with carboplatin (AUC 2)\
  Weekly paclitaxel and liposomal doxorubicin ×18 weeks\                                                                                        3-year EFS 76.1%         3-year EFS 85.8%                      More grade 3/4 anemia\
  + bevacizumab every 3 weeks ×6 cycles\                                                                                                                                                                       More grade 3/4 neutropenia\
  ± weekly carboplatin AUC 2×18 weeks                                                                                                                                                                          More grade 3/4 thrombopenia\
                                                                                                                                                                                                               More grade 3/4 diarrhea\
                                                                                                                                                                                                               Reduction of carboplatin AUC to 1.5 → reduced hematological events (from 82% to 70%) and nonhematological events (78% to 59%)

  **CALGB 40603, only TNBC[@b53-bctt-8-093]**\                                                                                            443   pCR 41% (ypT0/TisN0)\    pCR 54% (ypT0/TisN0)\                 Increased with carboplatin\
  Weekly paclitaxel ×12 weeks\                                                                                                                  3-year EFS 71.6%         3-year EFS 76.5%                      More grade 3/4 neutropenia\
  ± carboplatin AUC 6 every 3 weeks\                                                                                                                                                                           More grade 3/4 thrombopenia
  ×4 cycles/dose-dense anthracycline--cyclophosphamide ×4 cycles                                                                                                                                               

  **GEICAM/2006-03[@b54-bctt-8-093]**\                                                                                                    94    pCR 35% (ypT0N0)         pCR 30% (ypT0N0)                      No difference in grade 3/4 toxicity
  Epirubicin--cyclophosphamide every 3 weeks ×4 cycles/docetaxel every 3 weeks ×4 cycles\                                                                                                                      
  ± carboplatin AUC 6 every 3 weeks ×4 cycles                                                                                                                                                                  

  **I-SPY arm 1[@b55-bctt-8-093]**\                                                                                                       62    pCR 26% (ypT0N0)         pCR 52% (ypT0N0)                      More toxicity with carboplatin/veliparib\
  Weekly paclitaxel ×12 weeks/dose-dense doxorubicin--cyclophosphamide ×4 cycles\                                                                                                                              ≥ Hematological grade 3 events: 26.4% versus 4.5%
  ± veliparib and carboplatin                                                                                                                                                                                  

  **Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as neoadjuvant treatment in locally advanced TNBC[@b51-bctt-8-093]**\   91    pCR: 14% (ypT0/TisN0)\   pCR: 38.6% (ypT0/TisN0)\              No difference in grade 3/4 toxicity
  Paclitaxel--carboplatin AUC 5 every 3 weeks ×4--6 cycles or epirubicin--paclitaxel every 3 weeks ×4--6 cycles                                 4-year RFS 52.8%         4-year RFS 71.1%                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AUC, area under curve; EFS, event-free survival; is, in situ; pCR, pathologic complete response; RFS, relapse-free survival; TNBC, triple-negative breast cancer.

###### 

Trials in progress in the neoadjuvant and adjuvant settings for TNBC

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier                                                                                                                                                                                                       Phase, design   Treatment                                                                                                                         Primary outcome
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  **Neoadjuvant studies**                                                                                                                                                                                                                                                                                                                                                                                                   

  Neoadjuvant metronomic chemotherapy in TNBC\                                                                                                                                                                                                                            II\             AC/carboplatin + P                                                                                                                pCR rates
  NCT00542191                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Two consequent chemotherapy regimens as induction preoperative therapy for patients with locally advanced TNBC\                                                                                                                                                         II\             P + carboplatin/AC + capecitabine                                                                                                 pCR rates
  NCT01969032                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Personalized treatment of high-risk mammary cancer: the PETREMAC trial (personalized medicine)\                                                                                                                                                                         II\             Neoadjuvant olaparib/olaparib + carboplatin (if lack of response to olaparib alone)                                               Predictive and prognostic value of mutations in cancer-related genes assessed in breast cancer tissue before starting therapy
  NCT02624973                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Identification of BRCA1-associated DNA-repair dysfunction in patients with early TNBC treated with neoadjuvant platinum-based chemotherapy\                                                                                                                             II\             Cisplatin                                                                                                                         pCR rates
  NCT01672671                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Effect of neoadjuvant platinum-based chemoradiation therapy for locally advanced TNBC: clinical outcomes and correlation to biological parameters\                                                                                                                      II\             Carboplatin or cisplatin + radiotherapy                                                                                           CRR
  NCT01167192                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Impact of an additional four cycles of cisplatin in patients with TNBC not achieving clinical CR after four cycles of neoadjuvant adriamycin plus cyclophosphamide\                                                                                                     II\             Adriamycin + cyclophosphamide/cisplatin                                                                                           pCR rates
  NCT02001519                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  TBCRC030: preoperative cisplatin versus P in patients with TNBC: evaluating the homologous recombination-deficiency biomarker\                                                                                                                                          II\             P versus cisplatin                                                                                                                pCR rates
  NCT01982448                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  2×2 factorial trial of the addition of carboplatin ± bevacizumab to neoadjuvant weekly P followed by dose-dense AC in hormone receptor-poor/HER2-negative resectable breast cancer\                                                                                     II\             P/AC versus\                                                                                                                      pCR rates
  NCT00861705                                                                                                                                                                                                                                                             Randomized\     P/AC + carboplatin versus\                                                                                                        
                                                                                                                                                                                                                                                                          Open-label      P/AC + bevacizumab versus\                                                                                                        
                                                                                                                                                                                                                                                                                          P/AC + bevacizumab and carboplatin                                                                                                

  TBCRC 031: neoadjuvant cisplatin versus doxorubicin/cyclophosphamide in women with newly diagnosed breast cancer and germ-line *BRCA* mutations\                                                                                                                        II\             AC versus cisplatin                                                                                                               pCR rates
  NCT01670500                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Efficacy and safety of weekly P single agent and two different regimens of the PARP1 inhibitor SAR240550 (BSI-201) in combination with weekly P as neoadjuvant therapy in patients with stage II--IIIA TNBC\                                                            II\             Iniparib (different schedules and dosing) + P versus P alone                                                                      pCR rates
  (SOLTI NEOPARP)\                                                                                                                                                                                                                                                        Randomized\                                                                                                                                       
  NCT01204125                                                                                                                                                                                                                                                             Open-label                                                                                                                                        

  Different neoadjuvant regimens in subtypes of breast Cancer\                                                                                                                                                                                                            II\             TNBC subtype: carboplatin + P versus epirubicin + P                                                                               pCR rates
  NCT02041338                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Pathologic complete response with the addition of carboplatin with and without veliparib to standard chemotherapy in the neoadjuvant treatment of TNBC\                                                                                                                 II\             P + carboplatin/AC versus\                                                                                                        pCR rates
  NCT01818063                                                                                                                                                                                                                                                             Randomized\     P + carboplatin/AC + veliparib                                                                                                    
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Predictors of response to neoadjuvant docetaxel--carboplatin chemotherapy for patients with stage II and III TNBC\                                                                                                                                                      II\             Carboplatin--docetaxel                                                                                                            Predictors of response to docetaxel--carboplatin
  NCT01560663                                                                                                                                                                                                                                                             Observational                                                                                                                                     

  Individualized neoadjuvant chemotherapy in TNBC (neo-TN)\                                                                                                                                                                                                               II/III\         Platinum-based chemotherapy, but variable schedule based on HRD status and response                                               Average neoadjuvant response index
  NCT01057069                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Neoadjuvant carboplatin plus docetaxel or carboplatin plus P followed by AC in stage I--III TNBC\                                                                                                                                                                       III\            Carboplatin + docetaxel/AC versus carboplatin + P/AC                                                                              pCR rates
  NCT02413320                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Two dose-dense, dose-intensified approaches (ETC andPM\[Cb\]) for neoadjuvant treatment of patients withhigh-risk early breast cancer (GeparOcto)\                                                                                                                      III\            Carboplatin + Myocet + P versus epirubicin + P + cyclophosphamide                                                                 pCR rates
  NCT02125344                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Safety and efficacy of the addition of veliparib pluscarboplatin versus the addition of carboplatin to standardneoadjuvant chemotherapy versus standard neoadjuvantchemotherapy in subjects with early stage TNBC\                                                      III\            Veliparib + carboplatin + P followed by AC versus placebo + carboplatin + P followed by AC versus 2 placebos + P followed by AC   pCR rates
  NCT02032277                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Double-blind                                                                                                                                      

  **Neoadjuvant or adjuvant study**                                                                                                                                                                                                                                                                                                                                                                                         

  Anthracyclines followed by taxane versus anthracyclinesfollowed by taxane plus carboplatin as (neo)adjuvanttherapy in patients with TNBC (PEARLY trial)\                                                                                                                III\            AC/taxol versus\                                                                                                                  5-year EFS
  NCT02441933                                                                                                                                                                                                                                                             Randomized\     AC/taxol + carboplatin                                                                                                            
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  **Adjuvant studies, if residual disease after neoadjuvant chemotherapy**                                                                                                                                                                                                                                                                                                                                                  

  PARP inhibition after preoperative chemotherapy inpatients with TNBC or ER/PR^+^, HER2^−^ with known*BRCA1*/*2* mutations NCT01074970                                                                                                                                   II\             Cisplatin versus cisplatin + rucaparib                                                                                            2-year DFS
                                                                                                                                                                                                                                                                          Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Everolimus plus cisplatin in TNBC patients with residualdisease after standard chemotherapy (NECTAR trial)\                                                                                                                                                             II\             Cisplatin + everolimus                                                                                                            Tumor response
  NCT01931163                                                                                                                                                                                                                                                             Single-arm\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Postoperative trial of platinum-based chemotherapyversus observation in patients with residual TN basal-like breast cancer following neoadjuvant chemotherapy\                                                                                                          III\            Platinum-based chemotherapy (cisplatin or carboplatin) versus observation                                                         IDFS
  NCT02445391                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  Carboplatin as adjuvant chemotherapy versusobservation in TNBC with pathologic residual cancerafter neoadjuvant chemotherapy: POST-neoadjuvant study\                                                                                                                   III\            Carboplatin versus observation                                                                                                    DFS
  NCT01752686                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  **Adjuvant studies**                                                                                                                                                                                                                                                                                                                                                                                                      

  NRG BR-003: adjuvant therapy comparing AC followedby weekly P with or without carboplatin for node-positive or high-risk node-negative triple-negativeinvasive breast cancer\                                                                                           II\             Sequential treatment AC/P versus AC/P + carboplatin                                                                               IDFS
  NCT02488967                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Open-label                                                                                                                                        

  EC followed by docetaxel given every 3 weeks, weeklyP or weekly P plus carboplatin in TNBC (TPPC)\                                                                                                                                                                      II\             3 arms: EC/docetaxel versus\                                                                                                      3-year DFS
  NCT02455141                                                                                                                                                                                                                                                             Randomized\     EC/P versus\                                                                                                                      
                                                                                                                                                                                                                                                                          Open-label      EC/carboplatin + P                                                                                                                

  Efficacy and safety of olaparib versus placebo asadjuvant treatment in patients with germ-line *BRCA1*/*2*mutations and high-risk HER2-negative primary breastcancer who have completed definitive local treatmentand neoadjuvant or adjuvant chemotherapy (Olympia)\   III\            Olaparib versus placebo                                                                                                           IDFS
  NCT02032823                                                                                                                                                                                                                                                             Randomized\                                                                                                                                       
                                                                                                                                                                                                                                                                          Double-blind                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AC, doxorubicin + cyclophosphamide; CR, complete response; CRR, clinical response rate; DFS, disease-free survival; EC, epirubicin--cyclophosphamide; EFS, event-free survival; ETC, epirubicin--paclitaxel--cyclophosphamide; HRD, homologous recombination deficiency; IDFS, invasive DFS; PARP, poly ADP ribose polymerase; P, paclitaxel; pCR, pathologic complete response; PM(Cb), paclitaxel--Myocet (carboplatin); TNBC, triple-negative breast cancer.

###### 

Results of trials with PARP inhibitors in triple-negative breast cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier                                                                                                       Phase, design   Drug                                              Primary objective                                                                      Results
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Pharmacokinetic and biological evaluation of a small molecule inhibitor of PARP1 (KU-0059436) in patients with advanced tumors[@b60-bctt-8-093]\                        I\              Olaparib                                          Safety, tolerability, dose-limiting toxicity, and maximum tolerated dose of olaparib   60 patients\
  NCT00516373                                                                                                                                                             Open-label\                                                                                                                                              22 germ-line BRCA1/2\
                                                                                                                                                                          Single-arm                                                                                                                                               Mild toxicity\
                                                                                                                                                                                                                                                                                                                                   Durable objective response in only germ-line BRCA1/2 breast, ovarian, prostate cancers (63%)

  AZD2281 in patients with known BRCA mutation status or recurrent high-grade ovarian cancer or patients with known BRCA mutation status/TNBC[@b63-bctt-8-093]\           II\             Olaparib 400 mg                                   Objective response rate (ORR)\                                                         26 patients\
  NCT00679783                                                                                                                                                             Open-label\                                                       Complete response (CR)                                                                 ORR 0\
                                                                                                                                                                          Single-arm                                                                                                                                               CR 0

  Efficacy and safety of KU-0059436 (olaparib) given orally twice daily in patients with advanced BRCA1 or BRCA2-associated breast cancer[@b61-bctt-8-093]\               II\             Olaparib 100 mg twice daily, 400 mg twice daily   Confirmed objective tumor response CR\                                                 27 patients (100 mg)\
  NCT00494234                                                                                                                                                             Open-label\                                                       Overall response (OR) = CR + PR                                                        ORR 22%\
                                                                                                                                                                          Single-arm                                                                                                                                               CR 0\
                                                                                                                                                                                                                                                                                                                                   27 patients (400 mg)\
                                                                                                                                                                                                                                                                                                                                   ORR 41%\
                                                                                                                                                                                                                                                                                                                                   CR 0

  Efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA1 and/or BRCA2 mutation[@b62-bctt-8-093]\   II\             Olaparib 400 mg twice daily                       Tumor-response rate                                                                    62 patients\
  NCT01078662                                                                                                                                                             Open-label\                                                                                                                                              ORR 13%\
                                                                                                                                                                          Single-arm                                                                                                                                               CR 0
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** TNBC, triple-negative breast cancer.

###### 

First results with antiandrogen therapy in TNBC and studies in progress

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier                                                                  Phase, design   Drug                                    Primary outcome                                                                              Status           Results
  ---------------------------------------------------------------------------------------------------------------------------------- --------------- --------------------------------------- -------------------------------------------------------------------------------------------- ---------------- --------------------------
  Bicalutamide for the treatment of AR^+^, ER^−^, PR^−^ metastatic BC patients[@b70-bctt-8-093]\                                     II\             Bicalutamide 150 mg once daily          CBR at 6 months (CR, PR, stable disease)                                                     Closed           26 patients CBR 19%\
  NCT00468715                                                                                                                        Open-label\                                                                                                                                                           Median PFS 12 weeks
                                                                                                                                     Single-arm                                                                                                                                                            

  Clinical activity and safety of enzalutamide in patients with advanced, AR^+^ TNBC, stage 1[@b71-bctt-8-093]\                      II\             Enzalutamide 160 mg once daily          CBR at 16 weeks (CR, PR, stable disease)                                                     Not recruiting   26 patients CBR~16~ 42%
  NCT01889238                                                                                                                        Open-label\                                                                                                                                                           
                                                                                                                                     Single-arm                                                                                                                                                            

  Clinical activity and safety of enzalutamide in patients with advanced, AR^+^ TNBC, stage 2[@b72-bctt-8-093]\                      II\             Enzalutamide 160 mg once daily          CBR at 16 weeks (CR, PR, stable disease)                                                     Not recruiting   75 patients CBR~16~ 35%\
  NCT01889238                                                                                                                        Open-label\                                                                                                                                                           Median PFS 14.7 weeks
                                                                                                                                     Single-arm                                                                                                                                                            

  Activity of abiraterone acetate plus prednisone in patients with a molecular apocrine HER2^−^ locally advanced or metastatic BC\   II\             Abiraterone acetate 160 mg once daily   CBR at 6 months (CR, PR, stable disease)                                                     Not recruiting   Not available
  NCT01842321                                                                                                                        Open-label\                                                                                                                                                           
                                                                                                                                     Single-arm                                                                                                                                                            

  Orteronel as monotherapy in patients with metastatic BC that expresses the AR\                                                     II\             Orteronel 300 mg twice daily            Response rate at 36 months\                                                                  Recruiting       Not available
  NCT01990209                                                                                                                        Open-label\                                             Disease control rate at 36 months                                                                             
                                                                                                                                     Single-arm                                                                                                                                                            

  Bicalutamide as a treatment in AR-positive metastatic triple-negative breast cancer (mTNBC) patients\                              II\             Bicalutamide 150 mg once daily          CBR                                                                                          Recruiting       Not available
  NCT02348281                                                                                                                        Open-label\                                                                                                                                                           
                                                                                                                                     Single-arm                                                                                                                                                            

  AR inhibitor bicalutamide in treating patients with TNBC\                                                                          II\             Bicalutamide 150 mg once daily          CBR                                                                                          Recruiting       Not available
  NCT02353988                                                                                                                        Open-label\                                                                                                                                                           
                                                                                                                                     Single-arm                                                                                                                                                            

  Efficacy and safety of GTx-024 in patients with AR^+^ TNBC\                                                                        II\             GTx-024 18 mg once daily                CBR                                                                                          Recruiting       Not available
  NCT02368691                                                                                                                        Open-label\                                                                                                                                                           
                                                                                                                                     Single-arm                                                                                                                                                            

  Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of VT-464 in patients with advanced BC\                     I/II\           VT-464 once daily                       Phase I: maximum tolerated dose Phase II: CBR~16~ and CBR~24~ for patients with AR^+^ TNBC   Recruiting       Not available
  NCT02580448                                                                                                                        Open-label\                                                                                                                                                           
                                                                                                                                     Single-arm                                                                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BC, breast cancer; CBR, clinical benefit rate; CBR~16~, clinical benefit rate at 16; CBR~24~, clinical benefit rate at 24; CR, complete response; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free survival; PR, partial response; TNBC, triple-negative breast cancer; AR, androgen receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR-, progesterone receptor negative.

###### 

Immunotherapy trials in breast cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier                                                                                                                    Phase, design   Drug                                                                                                                                                 Primary outcome
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Neoadjuvant/adjuvant**                                                                                                                                                                                                                                                                                                                                  

  MEDI4736 (anti-PDL1 antibody) concomitant with weekly Nab-paclitaxel and dose-dense doxorubicin--cyclophosphamide chemotherapy for clinical stage I--III TNBC\                       Phase I/II\     Anti-PDL1 (MEDI4736) concomitant with Nab-paclitaxel and doxorubicin + cyclophosphamide                                                              pCR
  NCT02489448                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Triple-negative first-line study: neoadjuvant trial of Nab-paclitaxel and MPDL3280A, a PDL1 inhibitor, in patients with TNBC\                                                        Phase II\       Anti-PDL1 (MPDL3280A) in combination with Nab-paclitaxel                                                                                             pCR
  NCT02530489                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Safety and clinical activity of pembrolizumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for TNBC\                                                          Phase I\        Anti-PD1 (MK-3475, pembrolizumab) + chemotherapy versus MK-3475 + chemotherapy + carboplatin                                                         DLT, pCR
  NCT02622074                                                                                                                                                                          Randomized\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  **Metastatic**                                                                                                                                                                                                                                                                                                                                            

  Single-agent pembrolizumab (MK-3475) versus single-agent chemotherapy as per physician's choice for metastatic TNBC\                                                                 Phase III\      Anti-PD1 (MK-3475, pembrolizumab) versus chemotherapy                                                                                                PFS\
  NCT02555657                                                                                                                                                                          Randomized\                                                                                                                                                          OS
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Pembrolizumab (MK-3475) as monotherapy for metastatic TNBC\                                                                                                                          Phase II\       Anti-PD1 (MK-3475, pembrolizumab) monotherapy                                                                                                        ORR safety
  NCT02447003                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Nivolumab after induction treatment in TNBC patients: TONIC trial\                                                                                                                   Phase II\       Anti-PD1 (nivolumab) after induction treatment (four arms: radiotherapy, doxorubicin, cisplatin, cyclophosphamide) or noninduction treatment         PFS
  NCT02499367                                                                                                                                                                          Randomized\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Atezolizumab (MPDL3280A) (anti-PDL1 antibody) in combination with Nab-paclitaxel compared with placebo with Nab-paclitaxel for patients with previously untreated metastatic TNBC\   Phase III\      Anti-PDL1 (MPDL3280A, atezolizumab) with Nab-paclitaxel compared with placebo and Nab-paclitaxel                                                     PFS
  NCT02425891                                                                                                                                                                          Randomized\                                                                                                                                                          
                                                                                                                                                                                       Double-blind                                                                                                                                                         

  Tremelimumab monotherapy in patients with advanced solid tumors\                                                                                                                     Phase\          Anti-CTLA4 (tremelimumab) monotherapy with the option to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab after progressive disease   ORR
  NCT02527434                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Safety and efficacy of PDR001 administered to patients with advanced malignancies\                                                                                                   Phase I/II\     Anti-PD1 (PDR001) monotherapy                                                                                                                        Maximum tolerated dose Safety\
  NCT02404441                                                                                                                                                                          Single-arm\                                                                                                                                                          ORR
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Immuno-PET imaging with ^89^Zr-MPDL3280A in patients with locally advanced or metastatic non-small cell lung cancer, bladder cancer, or TNBC prior to MPDL3280A treatment\           Phase I\        ^89^Zr-MPDL380A (anti-PDL1)                                                                                                                          Description of 89Zr-MPDL380A PK by measuring SUV on the ^89^Zr-MPDL380A-PET scans → to evaluate the uptake of the tracer in tumor lesions and its use as a complementary tool for patient selection
  NCT02453984                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  MPDL3280A treatment in patients with locally advanced or metastatic non-small cell lung, bladder, and TNBC after investigational imaging\                                            Phase II\       Anti-PDL1 (MPDL380A)                                                                                                                                 ORR and efficacy
  NCT02478099                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Safety and pharmacokineticsof MPDL3280A administeredintravenously as a single agent topatients with locally advanced ormetastatic solid tumors or hematologicmalignancies\           Phase I\        Anti-PDL1 (MPDL3280A)                                                                                                                                Incidence and nature of DLT
  NCT01375842                                                                                                                                                                          Single-arm\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           

  Neoadjuvant study with the PDL1-directed antibody in locally advancedTNBC undergoing treatment withNab-paclitaxel and carboplatin\                                                   Phase III\      Carboplatin, Nab-paclitaxel, atezolizumab (MPDL3280A, anti-PDL1), anthracycline versus carboplatin, Nab-paclitaxel, and anthracycline                Event-free survival
  NCT02620280                                                                                                                                                                          Randomized\                                                                                                                                                          
                                                                                                                                                                                       Open-label                                                                                                                                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** DLT, dose-limiting toxicity; Nab, nanoparticle albumin-bound; ORR, objective response rate; OS, overall survival; pCR, pathologic complete response; PFS, progression-free survival; SUV, standardized uptake value; PK, pharmacokinetic; TNBC, triple-negative breast cancer; CTLA4, cytotoxic T-lymphocyte-associated protein 4; PD1, programmed cell death 1; PDL1, programmed death-ligand 1.
